Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 9, 2004 - Issue 1
Submit an article Journal homepage
55
Views
3
CrossRef citations to date
0
Altmetric
Review

The clinical application of monoclonal antibody therapies in renal transplantation

Kiran K Dhanireddy Transplantation Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National institutes of health, Room 11S/219, Building 10, Centre Drive, Bethesda, MD, USA. [email protected]
,
He Xu Transplantation Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National institutes of health, Room 11S/219, Building 10, Centre Drive, Bethesda, MD, USA. [email protected]
,
Roslyn B Mannon Transplantation Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National institutes of health, Room 11S/219, Building 10, Centre Drive, Bethesda, MD, USA. [email protected]
,
Douglas A Hale Transplantation Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National institutes of health, Room 11S/219, Building 10, Centre Drive, Bethesda, MD, USA. [email protected]
&
Allan D Kirk Transplantation Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National institutes of health, Room 11S/219, Building 10, Centre Drive, Bethesda, MD, USA. [email protected]
Pages 23-37 | Published online: 02 Mar 2005

Bibliography

  • US RENAL DATA SYSTEM: USRDS 2003 Annual Data Report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA (2003).
  • BILLINGHAM RE, BRENT L, MEDAWAR PB: Activity acquired tolerance of foreign cells. Nature (1953) 172 (4379) :603–606.
  • ••Landmark paper describing tolerance.
  • KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256(5517):495–497.
  • ••Landmark paper on the discovery ofmonoclonal antibodies.
  • STARZL TE, MARCHIORO TL, WADDELL WR: The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg. Gynecol Obstet. (1963) 117:385–395.
  • •Early paper using glucocorticoid immunosuppression in kidney transplantation.
  • TANPHAICHITR NT, BRENNAN DC: Infectious complications in renal transplant recipients. Adv. Ren. Replace. The]: (2000) 7(2):131–146.
  • PENN I: Cancers in renal transplant recipients. Adv. Ren. Replace. The]: (2000) 7(2):147–156.
  • SCHWENGER V, ZEIER M, RITZ E: Hypertension after renal transplantation. Ann. Transplant. (2001) 6(4):25–30.
  • PANNU HS, SINGH D, SANDHU JS: Lipid profile before and after renal transplantation-a longitudinal study. Ren. Fail (2003) 25(3):411–417.
  • SPRAGUE SM, JOSEPHSON MA: Bone disease after kidney transplantation. Semin. Nephrol (2004) 24(1):82–90.
  • PILMORE HL, DITTMER ID: Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin. Transplant. (2002) 16(3):191–195.
  • NANKIVELL BJ, BORROWS RJ, FUNG CL, O'CONNELL PJ, ALLEN RD, CHAPMAN JR: The natural history of chronic allograft nephropathy. N Engl. J. Med. (2003) 349(24):2326–2333.
  • LAFFERTY KJ, CUNNINGHAM AJ: A new analysis of allogeneic interactions. Aust. I Exp. Biol. Med. Sci. (1975) 53(1):27–42.
  • MATZINGER P: Tolerance, danger, andthe extended family. Ann. Rev Immunol 12:991–1045.
  • SCHROFF RW, FOON KA, BEATTY SM, OLDHAM RK, MORGAN AC JR: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. (1985) 45(2):879–885.
  • SHAWLER DL, BARTHOLOMEW RM, SMITH LM, DILLMAN RO: Human immune response to multiple injections of murine monoclonal IgG. Immunol (1985) 135(2):1530–1535.
  • BOULIANNE GL, HOZUMI N, SHULMAN MJ: Production of functional chimaeric mouse/human antibody. Nature (1984) 312(5995):643–646.
  • •Seminal paper on chimaeric antibody engineering.
  • MORRISON SL, JOHNSON MJ, HERZENBERG LA, OI VT: Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl Acad. Sci. USA (1984) 81(21):6851–6855.
  • •Seminal paper on chimaeric antibody engineering.
  • REICHMANN L, CLARK M, WALDMANN H, WINTER G: Reshaping human antibodies for therapy. Nature (1988) 332(6162):323–327.
  • •Seminal paper on humanised antibody engineering.
  • JONES PT, DEAR PH, FOOTE J, NEUBERGER MS, WINTER G: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 321(6069):522–525.
  • •Seminal paper on humanised antibody engineering.
  • MENDEZ MJ, GREEN LL, CORVALAN JR et al.: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. (1997) 15(2):146–156.
  • LEDBETTER JA, JUNE CH, MARTIN PJ, SPOONER CE, HANSEN JA, METER KE: Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation. ./. Immunol (1986) 136(10:3945–3952.
  • MARANO N, HOLOWKA D, BAIRD B: Bivalent binding of an anti-CD3 antibody to Jurkat cells induces association of the T cell receptor complex with the cytoskeleton. ./. Immunol (1989) 143(3):931–938.
  • TODD PA, BROGDEN RN: Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs (1989) 37(6):871–899.
  • GONCALVES LF, RAUBER ML, MANFRO RC, PROMPT CA: Fine needle aspiration biopsy in renal transplant patients on prophylactic OKT3 treatment. Transplant. Proc. (1992) 24(6):3085–3086.
  • WONG JT, EYLATH AA, GHOBRIAL I, COLVIN RB: The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging. Transplantation (1990) 50(4):683–689.
  • NORMAN DJ: Mechanisms of action and overview of OKT3. Ther. Drug Monit. (1995) 17(6): 615–620.
  • ORTHO MULTICENTER TRANSPLANT STUDY GROUP: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl. I Med. (1985) 313(6):337–342.
  • ••Landmark trial leading to first FDAapproval of a monoclonal antibody.
  • ABRAMOWICZ D, SCHANDENE L, GOLDMAN M et al: Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation (1989) 47(4):606–608.
  • CHATENOUD L, FERRAN C, LEGENDRE C et al: In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation (1990) 49(4):697–702.
  • COSTANZO-NORDIN MR: Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction. Transplant. Proc. (1993) 25(2 Suppl. 1):21–24.
  • GOLDSTEIN G, FUCCELLO AJ, NORMAN DJ, SHIELD CF 3rd, COLVIN RB, COSIMI AB: OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation (1986) 42(5):507–511.
  • ALEGRE ML, PETERSON LJ, XU D et al.: A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation (1994) 57(11):1537–1543.
  • WOODLE ES, XU D, ZIVIN RA et al: Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gammal (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation (1999) 68(5):608–616.
  • PARLEVLIET KJ, TEN BERGE IJ, YONG SL et al.: In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. Clin. Invest. (1994) 93(6):2519–2525.
  • MEIJER RT, SURACHNO S, YONG SL et al.: Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody. Clin. Exp. Immunol (2003) 133(3):485–492.
  • HENRY ML, PELLETIER RP, ELKHAMMAS EA, BUMGARDNER GL, DAVIES EA, FERGUSON RM: A randomized prospective trial of OKT3 induction in the current immunosuppression era. Clin. Transplant. (2001) 15(6):410–414.
  • FLECHNER SM, GOLDFARB DA, FAIRCHILD R et al.: A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Transplantation (2000) 69(11):2374–2381.
  • OH HK, PROVENZANO R, TAYEB J, SATMARY N, JONES B: Two low-dose OKT3 induction regimens following renal transplantation-clinical experience at a single center. arr. Transplant (1998) 12(4):343–347.
  • HALE G, WALDMANN H: CAMPATH-1 monoclonal antibodies in bone marrow transplantation. Hematother (1994) 3(1):15–31.
  • HALE G, SLAVIN S, GOLDMAN JM, MACKINNON S, GIRALT S, WALDMANN H: Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Bone Marrow Transplant. (2002) 30(12):797–804.
  • HALE G, BRIGHT S, CHUMBLEY G et al.: Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 62 (4) : 873–882.
  • FRIEND PJ, HALE G, WALDMANN H et al: Campath-1M-prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation (1989) 48(2):248–253.
  • FRIEND PJ, WALDMANN H, HALE G et al.: Reversal of allograft rejection using the monoclonal antibody, Campath-1G. Transplant. Proc. (1991) 23(4): 2253–2254.
  • KNECHTLE SJ, VARGO D, FECHNER J et al: FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation (1997) 63(1):1–6.
  • THOMAS JM, NEVILLE DM, CONTRERAS JL et al: Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation (1997) 64(1):124–135.
  • CALNE R, FRIEND P, MOFFATT S et al: Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 351(9117):1701–1702.
  • ••The first trial using alemtuzumab intransplantation and introducing the concept that depletional therapy can Induce prope tolerance.
  • CALNE R, MOFFATT SD, FRIEND PJ et al.: Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation (1999) 68(10):1613–1616.
  • KNECHTLE SJ, PIRSCH JD, H FECHNER J, JR et al: Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. I Transplant. (2003) 3(6):722–730.
  • LEVENTHAL JR, GALLON L, KAUFMAN DB et al: Alemtuzumab (Campath 1-H) facilitates prednisone-free immunosuppression (IP) in kidney transplant recipients. Am. J. Transplant. (2003) 3\(Suppl. 5):310.
  • KIRK AD, HALE DA, MANNON RB et al.: Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation (2003) 76(1):120–129.
  • ••The only trial to investigate the isolatedeffects of depletion in man.
  • WU Z, BENSINGER SJ, ZHANG J et al: Homeostatic proliferation is a barrier to transplantation tolerance. Nat. Med. (2004) 10(1):87–92.
  • DUSTIN ML, SANDERS ME, SHAW S, SPRINGER TA: Purified lymphocyte function-associated antigen 3 binds to CD2 and mediates T lymphocyte adhesion. Exp. Med. (1987) 165(3):677–692.
  • SAMELSON LE, FLETCHER MC, LEDBETTER JA, JUNE CH: Activation of tyrosine phosphorylation in human T cells via the CD2 pathway. Regulation by the CD45 tyrosine phosphatase. Immunol (1990) 145(8):2448–2454.
  • NIZET Y, CHENTOUFI AA, DE LA PARRA B et al: The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322. Transplantation (2000) 69(7):1420–1428.
  • BESSE T, MALAISE J, MOURAD M et al: Prevention of rejection with BTI-322 after renal transplantation (results at 9 months). Transplant. Proc. (1997) 29(5):2425–2426.
  • SPITZER TR, MCAFEE SL, DEY BR et al.: Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation (2003) 75(10):1748–1751.
  • THOMAS ML: The leukocyte common antigen family. Ann. Rev Immunol (1989) 7:339–369.
  • LYNCH KW, WEISS A: A model systemfor activation-induced alternative splicing of CD45 pre-mRNA in T cells implicates protein kinase C and Ras. Mol Cell. Biol. (2000) 20(1):70–80.
  • BINDON CI, HALE G, CLARK M, WALDMANN H: Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen. Synergy and interference in complement-mediated lysis. Transplantation (1985) 40(5):538–544.
  • CAMERON MJ, XU L, LONGSI R et al: Identification of gene expression profiles that correlate with tolerance induced by anti-CD45RB MAB treatment in a non-human-primate kidney allograft model. Am. I Transplant. (2003) 3 (Suppl. 5):263.
  • TANIGUCHI T, MINAMI Y: The IL-2/ IL-2 receptor system: a current overview. Cell. (1993) 73(1):5–8.
  • GOEBEL J, STEVENS E, FORREST K, ROSZMAN TL: Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl. Immunol (2000) 8(3):153–159.
  • VINCENTI F, KIRKMAN R, LIGHT S et al: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl. I Med. (1998) 338(3):161–165.
  • ••Pivotal trial with anti-IL-2R monoclonalantibodies and first important study using a humanised monoclonal antibodies.
  • MATAS AJ, GILLINGHAM KJ, PAYNE WD, NAJARIAN JS: The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation (1994) 57(6):857–859.
  • ADU D, COCKWELL P, IVES NJ, SHAW J, WHEATLEY K: Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. Br. Med. J. (2003) 326(7393):789.
  • WALTERS SJ, WHITFIELD M, AKEHURST RL, CHILCOTT JB: Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective. Pharmacoeconomics (2003) 21(2):129–138.
  • KEOWN PA, BALSHAW R, KRUEGER H, BALADI JF: Economic analysis of basiliximab in renal transplantation. Transplantation (2001) 71(10:1573–1579.
  • VINCENTI F, RAMOS E, BRATTSTROM C et al.: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation (2001) 71(9):1282–1287.
  • TRAN HT, ACHARYA MK, MCKAY DB et al: Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J. Am. Soc. Nephrol (2000) 11(10):1903–1909.
  • SARWAL MM, VIDHUN JR, ALEXANDER SR et al.: Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation (2003) 76(9):1331–1339.
  • •A good example of extended monoclonal antibody use suggesting applications other than induction therapy.
  • PEARSON TC, MADSEN JC, LARSEN CP, MORRIS PJ, WOOD KJ: Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation (1992) 54(3):475–483.
  • COSIMI AB, DELMONICO FL, WRIGHT JK et al.: Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody. Surgery (1990) 108(2):406–413.
  • DANTAL J, NININ E, HOURMANT M et al.: Anti-CD4 MoAb therapy in kidney transplantation-a pilot study in early prophylaxis of rejection. Transplantation (1996) 62(10):1502–1506.
  • COOPERATIVE CLINICAL TRIALS IN TRANSPLANTATION RESEARCH GROUP: Murine OKT4A immunosuppression in cadaver donor renal allograft recipients. Transplantation (1997) 63(9):1243–1251.
  • JUNE CH, LEDBETTER JA, GILLESPIE MM, LINDSTEN T, THOMPSON CB: T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell Biol. (1987) 7(12):4472–4481.
  • JUNE CH, LEDBETTER JA, LINDSTEN T, THOMPSON CB: Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. Immunol. (1989) 143(1):153–161.
  • JUNE CH, BLUESTONE JA, NADLER LM, THOMPSON CB: The B7 and CD28 receptor families. Immunol. Today (1994) 15(7):321–331.
  • JUNE CH, VANDENBERGHE P, THOMPSON CB: The CD28 and CTLA-4 receptor family. Chem. Immunol. (1994) 59:62–90.
  • THOMPSON CB, LINDSTEN T, LEDBETTER JA et al.: CD28 activation pathway regulates the production of multiple T-cell-derived lymphokinesi cytokines. Proc. Natl. Acad. Sci. USA (1989) 86(4):1333–1337.
  • BLAIR PJ, RILEY JL, CARROLL RG et al.: CD28 co-receptor signal transduction in T-cell activation. Biochem. Soc. Trans. (1997) 25(2):651–657.
  • BLAIR PJ, RILEY JL, LEVINE BL et al.: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bc1-X(L) induction. J. Immunol. (1998) 160(1):12–15.
  • SAYEGH MH, AKALIN E,HANCOCK WW et al.: CD28-B7 blockade after alloantigenic challenge in vivo inhibits Thl cytokines but spares Th2. I Exp. Med. (1995) 181(5):1869–1874.
  • SAYEGH MH, TURKA LA: T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J. Am. Soc. Nephrol. (1995) 6(4):1143–1150.
  • KIRK AD, TADAKI DK, CELNIKER A et al.: Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation (2001) 72(3):377–384.
  • KIRK AD, BLAIR PJ, TADAKI DK et al.: The role of CD154 in organ transplant rejection and acceptance. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2001) 356(1409):691–702.
  • SCHOENBERGER SP, TOES RE, VAN DER VOORT El, OFFRINGA R, MELIEF CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD4O-CD4OL interactions. Nature. (1998) 393(6684):480–483.
  • MIYASHITA T, MCILRAITH MJ, GRAMMER AC et al.: Bidirectional regulation of human B cell responses by CD4O-CD40 ligand interactions. Immunol. (1997) 158(10):4620–4633.
  • LIPSKY PE, ATTREP JF, GRAMMER AC, MCILRAITH MJ, NISHIOKA Y: Analysis of CD4O-CD40 ligand interactions in the regulation of human B cell function. Ann. NY Acad. Sci (1997) 815:372–383.
  • MATZINGER P: Graft tolerance: a duel of two signals. Nat. Med. (1999) 5(6):616–617.
  • ADAMS AB, SHIRASUGI N, DURHAM MM et al.: Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes (2002) 51(2):265–270.
  • ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. Clin. Invest. (1999) 103(9):1243–1252.
  • ADAMS AB, SHIRASUGI N, DURHAM MM et al.: Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes (2002) 51(2): 265–270.
  • VINCENTI F, DURBACH A, LARSEN C et al.: Study design and baseline characteristics of a multiple dose, randomized, controlled open-label study comparing a costimulation blocker based regimen of BMS-224818 (LEA29Y) versus cyclosporine in renal transplant. Am. J. Transplant. (2003) 3\(suppl 5):473.
  • •First concerted effort to develop a costimulatory blockade monoclonal antibody for transplantation. Subsequent results of this trial will be closely watched.
  • KIRK AD, HARLAN DM, ARMSTRONG NN et al.: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Nati Acad. Sri. USA (1997) 94(16):8789–8794.
  • KIRK AD, BURKLY LC, BATTY DS et al.: Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. (1999) 5(6):686–693.
  • •The most definitive result from a preclinical anti-rejection trial using only monoclonal antibody therapy.
  • KIRK AD, KNECHTLE SJ, SOLLINGER HW et al.: Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am. J. Transplant. (2001) l\(Suppl. 1):191.
  • KAWAI T, ANDREWS D, COLVIN RB, SACHS DH, COSIMI AB: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. (2000) 6(2):114.
  • HENN V, SLUPSKY JR, GRAFE M et al.: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. (1998) 391(6667):591–594.
  • KALUNIAN KC, DAVIS JC JR, MERRILL JT et al.: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46(12):3251–3258.
  • FUGGLE SV, KOO DD: Cell adhesion molecules in clinical renal transplantation. Transplantation. (1998) 65(6):763–769.
  • DUSTIN ML, SPRINGER TA: T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature. (1989) 341(6243):619–624.
  • LO SK, VAN SEVENTER GA, LEVIN SM, WRIGHT SD: Two leukocyte receptors (CD1 1 a/CD18 and CD1 1 b/ CD18) mediate transient adhesion to endothelium by binding to different ligands. Immunol. (1989) 143(10):3325–3329.
  • MENTZER SJ, GROMKOWSKI SH, KRENSKY AM, BURAKOFF SJ, MARTZ E: LFA1 membrane molecule in the regulation of homotypic adhesion of human B lymphocytes. I Immunol (1985) 135(1):9–11.
  • DAVIGNON D, MARTZ E, REYNOLDS T, KURZINGER K, SPRINGER TA: Monoclonal antibody to a novel lymphocyte function-associated antigen (LFA1): mechanism of blockade of T-lymphocyte mediated killing and effects on other T and B lymphocyte functions. Immunol (1981) 127(2):590–595.
  • HOURMANT M, BEDROSSIAN J, DURAND D et al: A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation (1996) 62(11):1565–1570.
  • MICHALLET MC, PREVILLE X, FLACHER M, FOURNEL S, GENESTIER L, REVILLARD JP: Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation (2003) 75(5):657–662.
  • DEDRICK RL, WALICKE P, GAROVOY M: Anti-adhesion antibodies efalizumab, a humanized anti-CD1 la monoclonal antibody. Transpl. Immunol (2002) 9(2-4):181–186.
  • DUSTIN ML, ROTHLEIN R, BHAN AK, DINARELLO CA, SPRINGER TA: Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). Immunol (1986) 137(1):245–254.
  • COSIMI AB, CONTI D, DELMONICO FL et al: In vivo effects ofmonoclonal antibody to ICAM-1 (CD54)in nonhuman primates with renal allografts.Immunol (1990) 144(12):4604–4612.
  • HAUG CE, COLVIN RB, DELMONICO FL et al: A Phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation (1993) 55(4):766–772.
  • SALMELA K, WRAMNER L, EKBERG H et al.: A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation (1999) 67(5):729–736.
  • GANNE V, SIDDIQIN, KAMAPLATH B et al.: Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin. Transplant. (2003) 17(5):417–422.
  • ALWAYN IP, XU Y, BASKER M et al.: Effects of specific anti-B anclior anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20-and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody. Xenotransplantation (2001) 8(3):157–171.
  • SAWADA T, FUCHINOUE S, TERAOKA S: Successful A1-to-0 ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation (2002) 74(9):1207–1210.
  • TYDEN G, KUMLIEN G, FEHRMAN I: Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation (2003) 76(4):730–731.
  • BECKER YT, PIRSCH JD, SOLLINGER HW: Rituximab: a highly successful therapy for treatment of vascular rejection. Am. Transplant. (2003) 3\(suppl 5):476.
  • SARWAL M, CHUA MS, KAMBHAM N et al.: Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl. I Med. (2003) 349(2):125–138.
  • HAO LM, WANG Y, GILL RG,LA ROSA FG, TALMAGE DW,LAFFERTY KJ: Role of lymphokine in islet allograft rejection. Transplantation (1990) 49(3):609–614.
  • DIAMOND AS, GILL RG: An essential contribution by IFN-gamma to CD8+ T cell-mediated rejection of pancreatic islet allografts. Immunol (2000) 165(1):247–255.
  • KIRK AD, HALE DA, HOFFMANN SC et al: Results from a human tolerance trial using Campath-1H with and without infliximab. Am. J. Transplant. (2002) 2\(Suppl. 2):379.

Websites

  • http://www.ama-assn.org/ama/pub/article/ 4781–4661.html AMA-USAN website. Accessed (2004).
  • http://www.immunetolerance.org/research/ solidorgan/trials/sachsl.html Immune Tolerance Network website. Accessed (2004).
  • http://www.immunetolerance.org/eXpress/ research/ 192003-1/vincenti.html Immune Tolerance Network Newsletter, Vol. 1 Number 1, July 2003. Accessed (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.